How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation?

BioEssays

Volumn 36, Issue 11, 2014, Pages 1082-1090

  Leprivier, Gabriel ^a,b   Sorensen, Poul H ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

EEF2 kinase (eEF2K); Metabolic stress; MRNA translation elongation; Oncogenes; Stress signaling

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; DEOXYGLUCOSE; ELONGATION FACTOR 2; ELONGATION FACTOR 2 KINASE; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAPAMYCIN; S6 KINASE; EEF2K PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; RAS PROTEIN;

ARTICLE; CALORIC RESTRICTION; CELL DEATH; CELL METABOLISM; CELL TRANSFORMATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MACROMOLECULE; MEDULLOBLASTOMA; MELANOMA; METABOLIC STRESS; NONHUMAN; NUCLEAR REPROGRAMMING; NUTRIENT AVAILABILITY; NUTRIENT DYNAMICS; NUTRIENT SUPPLY; ONCOGENE; OSMOTIC STRESS; OXIDATION REDUCTION STATE; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS INHIBITION; RNA TRANSLATION; SHORT TERM SURVIVAL; SYNTHESIS; TRANSLATION REGULATION; TUMOR CELL; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; ENERGY METABOLISM; GENETICS; METABOLISM; NEOPLASM;

APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ELONGATION FACTOR 2 KINASE; ENERGY METABOLISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; ONCOGENES; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 84907879675     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400085     Document Type: Article

References (64)

1. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-74.
2. Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134: 703-7.
3. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, et al. 2005. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-73.
4. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, et al. 2010. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38: 487-99.
5. Demetriades C, Doumpas N, Teleman AA. 2014. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell 156: 786-99.
6. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, et al. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-9.
7. Leprivier G, Remke M, Rotblat B, Dubuc A, et al. 2013. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153: 1064-79.
8. Qing G, Li B, Vu A, Skuli N, et al. 2012. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22: 631-44.
9. Shim H, Chun YS, Lewis BC, Dang CV. 1998. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-6.
10. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. 2009. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100: 865-9.
11. Jones RG, Thompson CB. 2009. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-48.
12. Flier JS, Mueckler MM, Usher P, Lodish HF. 1987. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235: 1492-5.
13. Osthus RC, Shim H, Kim S, Li Q, et al. 2000. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-800.
14. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-7.
15. Gao P, Tchernyshyov I, Chang TC, Lee YS, et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-5.
16. Shim H, Dolde C, Lewis BC, Wu CS, et al. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-63.
17. Buttgereit F, Brand MD. 1995. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 312: 163-7.
18. Jeon SM, Chandel NS, Hay N. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-5.
19. Yang ZJ, Chee CE, Huang S, Sinicrope FA. 2011. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10: 1533-41.
20. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-501.
21. Kaul G, Pattan G, Rafeequi T. 2011. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation. Cell Biochem Funct 29: 227-34.
22. Mathews MB, Sonenberg N, Hershey JWB. 2007. Translational Control in Biology and Medicine. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
23. Ovchinnikov LP, Motuz LP, Natapov PG, Averbuch LJ, et al. 1990. Three phosphorylation sites in elongation factor 2. FEBS Lett 275: 209-12.
24. Price NT, Redpath NT, Severinov KV, Campbell DG, et al. 1991. Identification of the phosphorylation sites in elongation factor-2 from rabbit reticulocytes. FEBS Lett 282: 253-8.
25. Wang X, Li W, Williams M, Terada N, et al. 2001. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20: 4370-9.
26. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. 2011. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-74.
27. Rahman MA, Salajegheh A, Smith RA, Lam AK. 2013. B-Raf mutation: a key player in molecular biology of cancer. Exp Mol Pathol 95: 336-42.
28. Kolibaba KS, Druker BJ. 1997. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1333: F217-48.
29. Browne GJ, Finn SG, Proud CG. 2004. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279: 12220-31.
30. Jeon SM, Hay N. 2012. The dark face of AMPK as an essential tumor promoter. Cell Logist 2: 197-202.
31. Hardie DG, Ross FA, Hawley SA. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251-62.
32. Browne GJ, Proud CG. 2002. Regulation of peptide-chain elongation in mammalian cells. Eur J Bio chem 269: 5360-8.
33. Gonzalez-Teran B, Cortes JR, Manieri E, Matesanz N, et al. 2013. Eukaryotic elongation factor 2 controls TNF-alpha translation in LPS-induced hepatitis. J Clin Invest 123: 164-78.
34. Holmes LE, Campbell SG, De Long SK, Sachs AB, et al. 2004. Loss of translational control in yeast compromised for the major mRNA decay pathway. Mol Cell Biol 24: 2998-3010.
35. Somers J, Poyry T, Willis AE. 2013. A perspective on mammalian upstream open reading frame function. Int J Biochem Cell Biol 45: 1690-700.
36. Fernandez J, Yaman I, Mishra R, Merrick WC, et al. 2001. Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. J Biol Chem 276: 12285-91.
37. Gaccioli F, Huang CC, Wang C, Bevilacqua E, et al. 2006. Amino acid starvation induces the SNAT2 neutral amino acid transporter by a mechanism that involves eukaryotic initiation factor 2alpha phosphorylation and cap-independent translation. J Biol Chem 281: 17929-40.
38. Holcik M, Sonenberg N. 2005. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-27.
39. Spriggs KA, Stoneley M, Bushell M, Willis AE. 2008. Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 100: 27-38.
40. Braunstein S, Karpisheva K, Pola C, Goldberg J, et al. 2007. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28: 501-12.
41. Stein I, Itin A, Einat P, Skaliter R, et al. 1998. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 18: 3112-9.
42. Ye J, Kumanova M, Hart LS, Sloane K, et al. 2010. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 29: 2082-96.
43. Holcik M, Lefebvre C, Yeh C, Chow T, et al. 1999. A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1: 190-2.
44. Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE. 2004. BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 279: 29066-74.
45. Ungureanu NH, Cloutier M, Lewis SM, de Silva N, et al. 2006. Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death. J Biol Chem 281: 15155-63.
46. Origanti S, Shantz LM. 2007. Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways. Cancer Res 67: 4834-42.
47. Fernandez J, Yaman I, Huang C, Liu H, et al. 2005. Ribosome stalling regulates IRES-mediated translation in eukaryotes, a parallel to prokaryotic attenuation. Mol Cell 17: 405-16.
48. Park S, Park JM, Kim S, Kim JA, et al. 2008. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 59: 70-83.
49. Sherman MY, Qian SB. 2013. Less is more: improving proteostasis by translation slow down. Trends Biochem Sci 38: 585-91.
50. Siller E, DeZwaan DC, Anderson JF, Freeman BC, et al. 2010. Slowing bacterial translation speed enhances eukaryotic protein folding efficiency. J Mol Biol 396: 1310-8.
51. Zhang G, Hubalewska M, Ignatova Z. 2009. Transient ribosomal attenuation coordinates protein synthesis and co-translational folding. Nat Struct Mol Biol 16: 274-80.
52. Fluitt A, Pienaar E, Viljoen H. 2007. Ribosome kinetics and aa-tRNA competition determine rate and fidelity of peptide synthesis. Comput Biol Chem 31: 335-46.
53. Hekman KE, Yu GY, Brown CD, Zhu H, et al. 2012. A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult. Hum Mol Genet 21: 5472-83.
54. Liu B, Han Y, Qian SB. 2013. Cotranslational response to proteotoxic stress by elongation pausing of ribosomes. Mol Cell 49: 453-63.
55. Shalgi R, Hurt JA, Krykbaeva I, Taipale M, et al. 2013. Widespread regulation of translation by elongation pausing in heat shock. Mol Cell 49: 439-52.
56. Kaufman RJ, Scheuner D, Schroder M, Shen X, et al. 2002. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3: 411-21.
57. Palorini R, Cammarata FP, Balestrieri C, Monestiroli A, et al. 2013. Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis 4: e732.
58. Ngoh GA, Hamid T, Prabhu SD, Jones SP. 2009. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol 297: H1711-9.
59. Teige M, Scheikl E, Reiser V, Ruis H, et al. 2001. Rck2, a member of the calmodulin-protein kinase family, links protein synthesis to high osmolarity MAP kinase signaling in budding yeast. Proc Natl Acad Sci USA 98: 5625-30.
60. Kalaany NY, Sabatini DM. 2009. Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-31.
61. Hursting SD, Dunlap SM, Ford NA, Hursting MJ, et al. 2013. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab 1: 10.
62. Mukherjee P, Abate LE, Seyfried TN. 2004. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10: 5622-59.
63. Conley SJ, Gheordunescu E, Kakarala P, Newman B, et al. 2012. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109: 2784-9.
64. Moserle L, Jimenez-Valerio G, Casanovas O. 2014. Antiangiogenic therapies: going beyond their limits. Cancer Discov 4: 31-41.